HVO.L
EquityHVIVO PLC ORD 0.1P
Health Care · Diagnostics & Research
$8.50
+8.50 (+0.00%)
Open
N/A
Day Range
$8.30 - $8.70
52W Range
$4.31 - $19.50
Volume
967K
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Fair Value Estimate
DDM Value
$4.20
Growth: 5.0% | Req. return: 10%
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | $3.61 | N/A | - | +0.00% |
| ABUS | Arbutus Biopharma Corporation | $4.66 | N/A | - | +0.00% |
| 001540.KQ | AHN-GOOK PHA | $8,070.00 | N/A | 5.45% | +0.00% |
| AHCO | AdaptHealth Corp. | $9.15 | N/A | - | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.31 | N/A | - | +0.00% |
| ABBV | AbbVie Inc. | $232.08 | N/A | 2.87% | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $24.56 | N/A | - | +0.00% |
| CRSP | CRISPR Therapeutics AG | $60.14 | N/A | - | +0.00% |
About HVIVO PLC ORD 0.1P
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and COPD. In addition, the company offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, it provides preclinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company offers services to big pharma and biotech organizations. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
www.hvivo.com →Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
Dividend History
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Dividend Growth
1Y CAGR
+0.0%
3Y CAGR
N/A
5Y CAGR
N/A
10Y CAGR
N/A
5-Year Dividend Projection
| Year | Conservative | Base | Optimistic |
|---|
Based on historical CAGR. Not a guarantee of future dividends.
View Full Projection →Loading financial data...
Revenue & Earnings
No financial statement data available for HVO.L.